Back

The utility of serial global longitudinal strain and biomarkers in identifying subclinical cardiotoxicity in cancer patients receiving anthracycline or trastuzumab therapy

11 December 2025 (10:30 - 11:15)
Organised by: Logo
Congress Presentation Part of: Role of echocardiography on cardio-oncology Systolic and Diastolic Function EACVI Premium Access EACVI 2025 European Association of Cardiovascular Imaging (EACVI)

About the speaker

Photo
Doctor Noha Shaaban

Alexandria University hospital, Alexandria (Egypt)

5 More presentations in this session

Presentation thumbnail
Valvular heart disease in cancer patients - prevalence, relevance, and therapeutic management - preliminary results from the CESAR study
Doctor M. Autherith (Vienna, AT)
Abstract Slides
Presentation thumbnail
Comprehensive echocardiographic assessment of the diastolic cardiac function in children treated for acute lymphoblastic leukemia, preliminary results.
Doctor J. Haponiuk-Skwarlinska (Warsaw, PL)
Abstract Slides
Presentation thumbnail
Dynamic cardiac toxicity monitoring in hematological tumor patients based on time thresholds and chemotherapy stratification
Doctor M. Zhang (Hangzhou, CN)
Abstract Slides
Presentation thumbnail
Echocardiographic and biochemical evidences of cardioprotection by dapagliflozin in non-diabetic models exposed to sequential anthracyclines and trastuzumab therapy
Doctor N. Maurea (Naples, IT)
Abstract Slides
Presentation thumbnail
Thick but safe: revisiting the role of epicardial adipose tissue in chemotherapy-induced cardiac dysfunction
Assistant Professor H. Kim (Cheonan-si, KR)
Abstract Slides

Access the full session

Session thumbnail
Role of echocardiography on cardio-oncology

The Event

Event poster

EACVI 2025

11 December 2025 10:30 CET
You may be interested in
thumbnail
Congress Session
Recent advances in clinical practice guidelines: what the imager needs to know and apply - Part 2
thumbnail
Congress Presentation
Diastolic function and left atrial pressures
thumbnail
Congress Presentation
Threshold values for diastolic dysfunction parameters indicative of increased mortality risk in a real-world patient cohort

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources